NextCell Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Aug '25 Aug 31, 2025	Dec '24 Dec 31, 2024	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Net Income	-40.14	-51.82	-35.89	-38.57	-43.17	-41
Depreciation & Amortization	1.87	3.36	2.52	0.43	0.97	0.45
Other Adjustments	1.14	0.89	0.74	1.04	1.21	1.19
Change in Receivables	-1.69	-1.7	-1.79	-2.05	3.17	-7.59
Changes in Inventories	0.22	0.22	0	0	0.25	-0.02
Changes in Accounts Payable	-0	-1.85	-4.45	-0.36	-0.21	3.15
Operating Cash Flow	-38.6	-50.9	-38.86	-39.51	-37.78	-43.83
Capital Expenditures	-3.22	-4.97	-0.42	-0.08	-0.08	-4.1
Purchases of Investments	-0.25	-0.3	-0.06	0	-0	-0
Investing Cash Flow	-3.47	-5.27	-4.24	-0.08	-0.08	-4.1
Long-Term Debt Issued	1.07	1.47	1.1	0.77	0.8	0.84
Net Long-Term Debt Issued (Repaid)	1.07	1.47	1.1	0.77	0.8	0.84
Issuance of Common Stock	51.33	33.93	36.56	0	33.83	-
Net Common Stock Issued (Repurchased)	51.33	33.93	36.56	0	33.83	-
Other Financing Activities	-2.91	-	-2.63	0	-	-
Financing Cash Flow	49.5	35.41	35.03	0.77	34.63	0.84
Net Cash Flow	7.43	-20.76	-8.07	-38.82	-3.23	-47.09
Free Cash Flow	-41.83	-55.87	-39.28	-39.6	-37.86	-47.92
FCF Margin	-394.08%	-400.18%	-355.03%	-351.10%	-335.70%	-343.41%
Free Cash Flow Per Share	-0.39	-0.65	-0.51	-0.97	-0.93	-1.39
Levered Free Cash Flow	-39.69	-52.69	-36.39	-41.2	-40.23	-39.5
Unlevered Free Cash Flow	-41.28	-55.06	-38.24	-43.19	-42.24	-41.53